Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CIT | O14578 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245334 | 0.81 | NISCH (0.35) | ROCK1KDRPDE3BNPC1ALDH1A1 | |
| SCHEMBL8418452 | 0.78 | ALDH1A1 (0.54) | NPC1MITFALDH1A1HTTRAB9A | |
| SCHEMBL8220090 | 0.76 | ROCK1 (0.40) | ROCK1NPC1MITFALDH1A1HTT | |
| SCHEMBL14494246 | 0.74 | KIF11 (0.48) | ROCK1HTTSMN1; SMN2 | |
| SCHEMBL8215666 | 0.74 | KIF11 (0.48) | ROCK1HTTSMN1; SMN2 | |
| SCHEMBL8208685 | 0.71 | SPHK1 (0.46) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8212572 | 0.70 | RAB9A (0.45) | NPC1MITFALDH1A1HTTRAB9A | |
| SCHEMBL8218365 | 0.70 | RNF4 (0.57) | NPC1MITFALDH1A1HTTRAB9A | |
| SCHEMBL8216616 | 0.70 | TSHR (0.49) | NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL8208426 | 0.70 | SPHK1 (0.51) | NPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007064732-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ROCK1 3702/4885KDR 2627/4885PDE3B 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.